Clinical trials: Melanoma Neoplasms
Neoplasms
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin.
- Trial name
- NCT00421811
- Testing
- ADH-1, melphalan
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Adherex Technologies, Inc.
Melanoma
iToBoS: Clinical Data Acquisition Study
The (overarching) iToBoS Project involves 18 research partners spanning the European Union (including UK and Israel), and 1 Australian partner.
- Trial name
- iToBoS (NCT05075356)
- Testing
- The intelligent total body scanner (iToBoS)
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Choroidal Melanoma, Indeterminate Lesions
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
To assess subject-centric evidence of QoL outcomes in a subset of subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Trial name
- NCT07421739
- Testing
- Non-interventional, digital, patient-reported, study
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Aura Biosciences
Melanoma
Post-ATU Study of Nivolumab
Nivolumab obtained European Marketing authorization in June 2015. Before this date, a Temporary Authorization for Use (ATU) Program in France for nivolumab was set up between September 2014 and August 2015.
- Trial name
- Post-ATU (NCT03325257)
- Testing
- Routine care
- Where
- 17 sites in France
- Volunteers
- 350 people
- Sponsor
- Nantes University Hospital
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Melanoma (Skin Cancer)
Investigation of the ROle of faT and inflAmmaTory Cells in mElanoma
This study is a retrospective, proof-of-concept sample study to investigate a novel histological finding within the primary melanoma tumour in a large population of melanoma patients to assess its prognostic significance.
- Trial name
- ROTATE (NCT07293598)
- Testing
- Sample analysis only
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- The Christie NHS Foundation Trust
Metastatic Melanoma
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Current therapeutic approaches available for patients with advanced-stage melanoma remain inadequate, and existing approaches including those involving immunotherapy with cytokines and/or targeted strategies have resulted in…
- Trial name
- NCT01876212
- Testing
- DC vaccine, Dasatinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Walter J. Storkus
Melanoma
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without…
- Trial name
- MelPORT (NCT04594187)
- Testing
- Immunotherapy, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
This phase III trial is aimed to investigate the efficacy of an individualized, sensitivity-directed combination chemotherapy in comparison to the standard regimen DTIC. Two question are aimed to be answered by this study: 1.
- Trial name
- ChemoSensMM (NCT00779714)
- Testing
- DTIC (dacarbazine), paclitaxel + cisplatin, treosulfan + cytarabine
- Where
- 23 sites in Germany
- Volunteers
- 360 people
- Sponsor
- University of Wuerzburg
Malignant Melanoma
Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma
Postoperative complications like seroma formation and wound site infection readily occur following completion axillary lymph node dissection (ALND) for malignant melanoma.
- Trial name
- NCT04648163
- Where
- Austria
- Volunteers
- 118 people
- Sponsor
- Medical University of Graz
Stage IV Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
This study evaluates the effectiveness of adding a single four-day treatment of the fusion protein A-dmDT390-bisFv(UCHT1) - plus single palliative tumor radiation - with standard of care KEYTRUDA (Pembrolizumab) therapy for the…
- Trial name
- NCT02990416
- Testing
- A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Virogen Biotechnology Inc.
Melanoma, Cancer Survivorship
Mentored Community Gardening for Individuals With Skin Cancer
The investigators will conduct a single-arm pilot feasibility trial of mentored community gardening for melanoma survivors integrating dosimeters and accelerometers.
- Conditions
- Melanoma, Cancer Survivorship, Skin Cancer, Basal Cell Carcinoma
- Trial name
- H4H2-AZ (NCT05648604)
- Testing
- Mentored Community Gardening
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Melanoma
The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma
This is a monocentric prospective study. This study aims to investigate the prognostic value of the novel melanin-targeted imaging modality 18F-PFPN PET in patients with melanoma and seek independent prognostic factors for…
- Trial name
- NCT05645484
- Testing
- 18F-PFPN, 18F-FDG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Melanoma, Cancer
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Primary objective: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment.
- Trial name
- NCT00613509
- Testing
- ALVAC(2) Melanoma multi-antigen therapeutic vaccine, Intron A, Interferon alpha -2b
- Where
- 19 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Non-melanoma Skin Cancer
Dermoscopy and Histopathology in Non-melanocytic Skin Tumors
The main aim of the study is to investigate the relation between dermoscopic findings in pre-operative diagnosis of non-melanocytic skin tumors and post-operative histopathology findings .
- Trial name
- NCT06523816
- Testing
- dermoscopy
- Volunteers
- 20 people
- Sponsor
- Assiut University
Solid Tumor
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
The primary objective of this study is to evaluate the safety of Neo-T in combination with anti-PD1 in patients with solid tumors.
- Trial name
- NCT05798533
- Testing
- Neo-T, Toripalimab, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- BGI, China
Melanoma, Non-melanoma Skin Cancer
DERM Health Economics Study
This study aims to provide an initial assessment of the potential impact DERM could have on the number of onward referrals for a face to face dermatologist review and/or biopsy from a teledermatology-based service, and to improve…
- Trial name
- NCT04123678
- Testing
- Deep Ensemble for the Recognition of Malignancy (DERM)
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- Skin Analytics Limited
Cutaneous Tumor, Optical Coherence Tomography
Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)
This project aims to validate ex vivo the use of the OCTAV® prototype integrating the "dermoscope" function before an in vivo application, by comparing images obtained by the OCTAV® prototype integrating the "dermoscope" function…
- Conditions
- Cutaneous Tumor, Optical Coherence Tomography, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- DERMOCTAV (NCT05340543)
- Testing
- Confocal optical coherence tomography - OCTAVE
- Where
- France
- Volunteers
- 150 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Choroidal Melanoma
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that…
- Trial name
- NCT01251978
- Testing
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New England Retina Associates
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.